Watchlist Price Alert

Hamilton Lane (HLNE)

NASDAQ: HLNE · Real-Time Price · USD

162.82

0.12 (0.07%)

At close: May 09, 2025, 3:59 PM

162.68

-0.09%

After-hours: May 09, 2025, 04:05 PM EDT

0.07% (1D)

Bid	150.8
Market Cap	9.28B
Revenue (ttm)	691.66M
Net Income (ttm)	215.28M
EPS (ttm)	5.41
PE Ratio (ttm)	30.1
Forward PE	31.19
Analyst	Hold

Ask	168.84
Volume	236,501
Avg. Volume (20D)	570,732
Open	162.70
Previous Close	162.70
Day's Range	161.17 - 164.00
52-Week Range	114.25 - 203.72
Beta	1.33

About HLNE

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol HLNE

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for HLNE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Hamilton Lane is scheduled to release its earnings on May 29, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+16.13%

Shares of companies within the broader financial s... Unlock content with Pro Subscription

1 month ago

-3.71%

Shares of companies within the broader financial sector are trading lower in response to President Trump's sweeping Liberation tariffs and retaliatory responses. The sector is now facing greater macroeconomic uncertainty and recession fears.

News

1 month ago · zacks.com

Hamilton Lane (HLNE) Surges 16.1%: Is This an Indication of Further Gains?

Hamilton Lane (HLNE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down t...

2 months ago · youtube.com

Hamilton Lane co-CEO Erik Hirsch on what is gumming up the IPO pipeline right now

Erik Hirsch, Hamilton Lane Co-CEO, joins 'Closing Bell Overtime' to talk why the IPO boom isn't materializing.

2 months ago · businesswire.com

Cosette Pharmaceuticals Announces Acquisition of Mayne Pharma, Transforming Company into a Leader in Women's Health and Dermatology

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has entered into a definitive agreement to acquire al...

3 months ago · seekingalpha.com

Hamilton Lane Q3 Earnings: Slowing Momentum, But Shares Remain Expensive

Q3 results showed revenue up 34% year over year, coupled with strong overall profitability, both benefiting from higher incentive fees. Underlying growth in assets under management/advisement was mute...